key: cord-0838348-6gillp60 authors: Case, James Brett; Rothlauf, Paul W.; Chen, Rita E.; Liu, Zhuoming; Zhao, Haiyan; Kim, Arthur S.; Bloyet, Louis-Marie; Zeng, Qiru; Tahan, Stephen; Droit, Lindsay; Ilagan, Ma. Xenia G.; Tartell, Michael A.; Amarasinghe, Gaya; Henderson, Jeffrey P.; Miersch, Shane; Ustav, Mart; Sidhu, Sachdev; Virgin, Herbert W.; Wang, David; Ding, Siyuan; Corti, Davide; Theel, Elitza S.; Fremont, Daved H.; Diamond, Michael S.; Whelan, Sean P.J. title: Neutralizing antibody and soluble ACE2 inhibition of a replication-competent VSV-SARS-CoV-2 and a clinical isolate of SARS-CoV-2 date: 2020-05-18 journal: bioRxiv DOI: 10.1101/2020.05.18.102038 sha: b8de9e9be00cfed1ff64c5c6dff807373120d7da doc_id: 838348 cord_uid: 6gillp60 Antibody-based interventions against SARS-CoV-2 could limit morbidity, mortality, and possibly disrupt epidemic transmission. An anticipated correlate of such countermeasures is the level of neutralizing antibodies against the SARS-CoV-2 spike protein, yet there is no consensus as to which assay should be used for such measurements. Using an infectious molecular clone of vesicular stomatitis virus (VSV) that expresses eGFP as a marker of infection, we replaced the glycoprotein gene (G) with the spike protein of SARS-CoV-2 (VSV-eGFP-SARS-CoV-2) and developed a high-throughput imaging-based neutralization assay at biosafety level 2. We also developed a focus reduction neutralization test with a clinical isolate of SARS-CoV-2 at biosafety level 3. We compared the neutralizing activities of monoclonal and polyclonal antibody preparations, as well as ACE2-Fc soluble decoy protein in both assays and find an exceptionally high degree of concordance. The two assays will help define correlates of protection for antibody-based countermeasures including therapeutic antibodies, immune γ-globulin or plasma preparations, and vaccines against SARS-CoV-2. Replication-competent VSV-eGFP-SARS-CoV-2 provides a rapid assay for testing inhibitors of SARS-CoV-2 mediated entry that can be performed in 7.5 hours under reduced biosafety containment. 4 (Hoffmann et al., 2020; Lei et al., 2020; Ou et al., 2020) . Such pseudotyping approaches are used 68 routinely by many laboratories for other highly pathogenic coronaviruses including SARS-CoV 69 and MERS-CoV (Fukushi et al., 2006; Fukushi et al., 2005; Giroglou et al., 2004; Kobinger et al., Here, we developed a simple and robust BSL2 assay for evaluating SARS-CoV-2 entry 82 and its inhibition by antibodies. We engineered an infectious molecular clone of vesicular 83 stomatitis virus (VSV) to encode the SARS-CoV-2 S protein in place of the native envelope 84 glycoprotein (G) and rescued an autonomously replication-competent virus bearing the spike. Through passage of VSV-eGFP-SARS-CoV-2, we selected a gain-of-function mutation in S that 86 allowed more efficient viral propagation yielding titers of > 1 x 10 8 plaque-forming units (PFU)/ml. We characterized this variant with respect to inhibition by soluble human ACE2-Fc and 88 monoclonal and polyclonal antibodies from humans and compared those results to neutralization 89 tests with a clinical isolate of SARS-CoV-2. These studies demonstrate that a recombinant VSV 90 expressing SARS-CoV-2 S behaves analogously to a clinical isolate of SARS-CoV-2, providing a 91 useful high-throughput BSL2 assay for studying antibody neutralization or inhibition of viral spike-92 mediated entry. A replication-competent, infectious VSV chimera with SARS-CoV-2 S protein. To 95 generate a replication-competent virus to study entry and neutralization of SARS-CoV-2 at BSL2, 96 we engineered an infectious molecular clone of VSV by replacing the endogenous glycoprotein 97 (G) with SARS-CoV-2 S (Fig 1A) . SARS-CoV-2 S protein contains an endoplasmic reticulum (ER) 98 retention sequence in the cytoplasmic tail (KxHxx-COOH) because virion assembly occurs in ER- Golgi intermediate compartments (Lontok et al., 2004; McBride et al., 2007; Ruch and Machamer, 100 2012). We preemptively altered that sequence to AxAxx to facilitate retargeting of S to the plasma 101 membrane, the site of VSV assembly. Using established approaches (Fig S1A) (Whelan et al., 102 1995), we recovered infectious VSV-eGFP-SARS-CoV-2-SAA as determined by expression of the 103 virus-encoded eGFP reporter (Fig 1A, right panel) . VSV-eGFP-SARS-CoV-2-SAA propagation 104 was inefficient on Vero CCL81 cells. This result prompted us to test additional modifications of 105 the cytoplasmic tail of S, which were also defective in autonomous amplification (Fig S1B) . To 106 overcome this limitation, we used a forward genetic approach to isolate an adaptive variant of 107 VSV-eGFP-SARS-CoV-2-SAA ( Fig S1C) . Repeated passage and plaque isolation on Vero CCL81 108 cells led to the emergence of a virus that contained a cysteine to stop mutation at residue 1253 109 (TGC to TGA at nucleotide 3759), which truncates the cytoplasmic tail of SARS-CoV-2 S by 21 110 residues (Fig 1A) . We confirmed that this was the only mutation in the viral genome by next 111 generation sequencing (Supplemental Data). Comparison of plaque morphology of VSV-eGFP-112 SARS-CoV-2-SΔ21 and VSV-eGFP-SARS-CoV-2-SAA on three Vero cell subtypes and an 113 additional rhesus monkey cell line (MA104) demonstrates that the selected variant spreads more 114 efficiently (Fig 1B) . Screening of a larger panel of cell types (Fig 1C) identified MA104 and Vero 115 E6 cells as supporting the highest levels of virus production. Ectopic expression of TMPRSS2 led 116 to a further ~10-fold increase in viral titer and a larger plaque size (Fig 1D) . incorporation of SARS-CoV-2 S into particles, we first amplified the virus in the presence of VSV 119 6 G to allow infection of cell types independently of the S protein. The VSV G trans-complemented 120 VSV-SARS-CoV-2-SΔ21 efficiently infects HEK293T cells, which then serve as a source of 121 production of virus particles containing SARS-CoV-2 S protein. Western blotting of supernatants 122 with CR3022, a cross-reactive anti-S monoclonal antibody (mAb) (ter Meulen et al., 2006; Yuan 123 et al., 2020) , established the presence of SΔ21 in VSV-SARS-CoV-2-SΔ21 particles but not in the 124 parental VSV (Fig 1E) . The protein detected migrated at ~100 kilodaltons, a band that 125 corresponds to the cleaved S1 subunit of the glycoprotein (Watanabe et al., 2020) . To examine 126 whether the SΔ21 incorporated into VSV particles is processed to S1 and S2, we performed [ 35 S] 127 cysteine-methionine metabolic labeling in BSRT7 cells, which support robust VSV replication, and 128 analyzed released particles by SDS-PAGE and phosphorimaging. In addition to the VSV 129 structural proteins (N, P, M and L), two additional bands were observed for VSV-SARS-CoV-2-130 SΔ21 that correspond in size to glycosylated S1 (107 kDa) and S2Δ21 (85 kDa) (Fig 1F) . Negative-131 stain electron microscopy of sucrose-gradient purified virus particles revealed that the membrane 132 protein projecting from VSV-SARS-CoV-2-SΔ21 is larger than observed on wild-type VSV particles 133 (Fig 1G) , which reflects the larger size of the coronavirus spike. A high-throughput focus-forming assay with a clinical isolate of SARS-CoV-2. VSV-135 SARS-CoV-2-SΔ21 has several advantages for detection and measuring of neutralizing antibodies, 136 including lower biosafety containment level, ease of production and use, and rapid reporter gene 137 readout. Nonetheless, the difference in virus morphology (spherical CoV versus bullet-shaped 138 VSV) and possible effects on the conformational display of S on the virion surface, raise questions 139 as to whether the accessibility of epitopes and stoichiometry of antibody neutralization is similar 140 to authentic SARS-CoV-2. A direct comparison with a clinical isolate of SARS-CoV-2 is necessary 141 to establish the utility of VSV-SARS-CoV-2-SΔ21 for assays of viral entry and antibody 142 neutralization. We designed a high-throughput assay for titrating SARS-CoV-2 that could be applied to 144 multiple cell substrates. Instead of using a plaque assay, which relies on the capacity for a virus 7 to cause cell death, which can vary across cell types, we developed a focus-forming assay (FFA) 146 and viral antigen detection as a measure of infectivity. We propagated SARS-CoV-2 in four 147 different producer cell types (Vero CCL81, Vero E6, Vero-furin, and MA104 cells) and then 148 measured the number and size of foci after staining recipient cells with an anti-S mAb. With SARS- CoV-2 stocks generated from each producer cell type, we observed distinct foci across recipient 150 cell substrates at approximately 30 h post-inoculation (Fig 2A) . We consistently observed the 151 highest viral titers and largest foci sizes with Vero-furin and MA104 cells (Fig 2B-C) . However, 152 the larger foci were more difficult to enumerate on an automated Immunospot reader and required 153 additional manual quality control analysis. Because of this, we used Vero E6 cells for our rapid reduction neutralization test (GRNT) (Fig 2D) . Neutralization of VSV-SARS-CoV-2-SΔ21 and SARS-CoV-2 by human antibodies. Members of our group recently identified human mAbs from memory B cells of a SARS-CoV 163 survivor that bind to SARS-CoV-2 S (Pinto et al, 2020) . We tested a subset of these (mAbs 304, Many of these mAbs exhibited moderate neutralization activities in the EC50 range of 100 to 500 8 ng/mL (Fig 3C-D) . Nonetheless, we observed the same neutralization trend between VSV-SARS- CoV-2-SΔ21 and SARS-CoV-2 with highly correlated EC50 values (< 2-fold differences). dose-dependently and equivalently inhibited infection of recipient Vero E6 cells (Fig 3E-F) . As 181 expected, hACE2-Fc did not inhibit infection of wild-type VSV confirming that neutralization was 182 specific to the SARS-CoV-2 S protein (Fig S2) . We noted a relatively high concentration of 183 hACE2-Fc was required for inhibition with EC50 values of 29 and 12.6 μg/ml for VSV-SARS-CoV- Neutralization of VSV-SARS-CoV-2-SΔ21 and SARS-CoV-2 by human immune serum. As part of studies to evaluate immune convalescent plasma as a possible therapy for SARS-CoV- (Table 1) . These samples were pre-192 screened using a commercially available IgG ELISA. We tested each sample for neutralization of 193 VSV-SARS-CoV-2-SΔ21 and SARS-CoV-2 on Vero E6 cells. We observed that sera with ELISA 194 negative or indeterminate results generally showed low inhibitory titers (EC50 <1/100), whereas 195 ELISA positive sera generated a broad range of neutralizing antibody activity (EC50 > 1/200 to 9 >1/1,900) (Fig 4A and C, Fig S3) . Remarkably, neutralization of VSV-SARS-CoV-2-SΔ21 and 197 SARS-CoV-2 was similar across the entire panel of samples (Fig 4B and C, Fig S3) . activity. Here, we generated a high-titer, replication-competent chimeric VSV expressing the 215 SARS-CoV-2 S protein that performs similarly to a SARS-CoV-2 clinical isolate across multiple 216 neutralization tests. As access to BSL3 facilities is limited, the finding that VSV-SARS-CoV-2-SΔ21 217 is neutralized similarly by decoy receptors, mAbs, and polyclonal antibodies in comparison to 218 authentic SARS-CoV-2 is important. This tool will enable academic, government, and industry 219 investigators to rapidly perform assays that interrogate SARS-CoV-2 entry, neutralization, and 220 inhibition at a BSL2 level, which should simplify and expedite the discovery of therapeutic 221 interventions and analysis of functional humoral immune responses. Upon recovery of VSV-SARS-CoV-2-SAA, we selected for a mutant, which contained a 21-223 amino acid deletion in the cytoplasmic tail. As truncation of the cytoplasmic tail eliminates the 224 modified KxHxx ER retention signal, we suggest that this mutation facilitates more efficient 225 incorporation of the SARS-CoV-2 S protein into the VSV particles. Although truncation of the 226 cytoplasmic tail of HIV envelope protein resulted in conformational alterations in the ectodomain 227 of the protein (Chen et al., 2015) , based on the extensive neutralization data presented here 228 including correlation to neutralization of a clinical isolate of SARS CoV-2, a 21-amino acid 229 truncation does not appear to substantively alter the structure of the S protein ectodomain. It 230 remains to be determined whether fully wild-type S protein can incorporate efficiently into VSV. Indeed, similar mutations were generated in the SARS-CoV S protein cytoplasmic tail to boost 232 incorporation into retroviruses and VSV pseudotypes (Fukushi et al., 2005; Giroglou et al., 2004; 11 The value of a chimeric virus depends on its capacity to present viral surface antigens in 235 a similar way to its authentic counterpart (Garbutt et al., 2004) . Indeed, the morphology of the 236 bullet-shaped rhabdovirus and the spherical coronavirus and the density and geometry of S 237 protein display could differentially impact antibody engagement and neutralization. Despite this 238 concern, our extensive testing of VSV-SARS-CoV-2-SΔ21 with antibodies and soluble ACE2-Fc 239 proteins showed similar neutralization profiles compared to authentic, fully infectious SARS-CoV- CoV-2. Indeed, convalescent plasma is under investigation as a potential COVID-19 therapeutic 243 (Chen et al., 2020) . Our studies suggest that in addition to testing for anti-S or anti-RBD antibodies 244 (Shen et al., 2020) , neutralization assays with VSV-SARS-CoV-2-SΔ21 may be a convenient and 245 rapid method to obtain functional information about immune plasma preparations to enable 246 prioritization prior to passive transfer to COVID-19 patients. Coronaviruses possess a roughly 30 kb RNA genome, which requires that they encode a Plasmids. The S gene of SARS-CoV-2 isolate Wuhan-Hu-1 (GenBank MN908947.3) was 367 synthesized in two fragments (Integrated DNA Technologies) and inserted into an infectious 368 molecular clone of VSV (Whelan et al., 1995) as previously (Carette et al., 2011; Jae et al., 2014) . Modifications to the cytoplasmic tail were assembled identically. Other plasmids were previously 370 described: VSV N, P, L and G expression plasmids (Stanifer et al., 2011; Whelan et al., 1995) , 371 psPAX2 (Addgene), and pLX304-TMPRSS2 (Zang et al., 2020) . Following four rounds of selection, phage ELISAs were used to screen 384 clones to identify 430 those that bound specifically to RBD. The complementarity determining regions of Fab-phage 431 clones were decoded by sequencing the variable regions and cloning them into mammalian 432 expression vectors for expression and purification of human IgG1 proteins, as described (Tao et 433 al., 2019) . A subset of the panel of mAbs was tested for neutralization as a part of this study. Another set of mAbs (S304, S306, S309, S310 and S315) were isolated from EBV-435 immortalized memory B cells from a SARS-CoV survivor (Traggiai et al., 2004) and are cross- Protein expression and purification. DNA fragments encoding human ACE2 (hACE2 446 residues 1-615) and mouse ACE2 (mACE2, residues 1-615) were synthesized and cloned into 447 pFM1.2 with a C-terminal HRV-3C protease cleavage site (LEVLFQGP) and a human IgG1 Fc 448 region as previously described (Raj et al., 2013) . We transiently transfected plasmids into Human immunodeficiency viral vector pseudotyped with the spike envelope of severe acute 537 respiratory syndrome coronavirus transduces human airway epithelial cells and dendritic cells. Hum Gene Ther 18, 413-422. Kruse, R.L. (2020). Therapeutic strategies in an outbreak scenario to treat the novel coronavirus 541 originating in Wuhan, China. F1000Research 9, 72. Lei, C., Qian, K., Li, T., Zhang, S., Fu, W., Ding, M., and Hu, S. (2020) . Neutralization of SARS- Ou, X., Liu, Y., Lei, X., Li, P., Mi, D., Ren, L., Guo, L., Guo, R., Chen, T., Hu, J., et al. (2020) . Characterization of spike glycoprotein of SARS-CoV-2 on virus entry and its immune cross-577 reactivity with SARS-CoV. Nat Commun 11, 1620. Persson, H., Ye, W., Wernimont, A., Adams, J.J., Koide, A., Koide, S., Lam, R., and Sidhu, S.S. (2013). CDR-H3 diversity is not required for antigen recognition by synthetic antibodies. J Mol Biol 425, 803-811. Asymptomatic Carrier Transmission of COVID-19 Deployment of convalescent plasma 489 for the prevention and treatment of COVID-19 Ebola virus entry requires the 493 cholesterol transporter Niemann-Pick C1 HIV-1 ENVELOPE. Effect of the cytoplasmic domain on antigenic 497 characteristics of HIV-1 envelope glycoprotein Cross-neutralization of 587 SARS-CoV and SARS-CoV-2 by a human monoclonal 2 antibody Dipeptidyl peptidase 4 is a functional receptor for the 591 emerging human coronavirus-EMC The coronavirus E protein: assembly and beyond Treatment of 5 Critically Ill Patients With COVID-19 With Convalescent Plasma A recombinant vesicular stomatitis virus 600 bearing a lethal mutation in the glycoprotein gene uncovers a second site suppressor that restores 601 fusion Specificity, cross-reactivity, and function of 605 antibodies elicited by Zika virus infection Tailored tetravalent antibodies potently and specifically activate 609 Wnt/Frizzled pathways in cells, organoids and mice Human monoclonal antibody 613 combination against SARS coronavirus: synergy and coverage of escape mutants Structural insights into coronavirus entry An efficient method to make human monoclonal 621 antibodies from memory B cells: potent neutralization of SARS coronavirus Antigenicity of the SARS-CoV-2 Spike Glycoprotein Site-specific glycan 628 analysis of the SARS-CoV-2 spike Efficient recovery of infectious 631 vesicular stomatitis virus entirely from cDNA clones Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation A highly conserved cryptic epitope in the receptor-binding domains of SARS-CoV-2 and SARS-638 CoV-2 infection of human small intestinal enterocytes Probable Pangolin Origin of SARS-CoV-2 Associated 645 with the COVID-19 Outbreak A pneumonia outbreak associated with a new coronavirus of probable bat 649 origin